Table 1.
Current US FDA-approved GLP-1 receptor agonists for type 2 diabetes mellitus
| Brand name | Generic name | Maximum dose | Frequency | Drug company | Date of approval | Indication |
|---|---|---|---|---|---|---|
| Byetta28 | Exenatide | 10 µg | Twice daily | AstraZeneca | 2005 | T2DM |
| Bydureon29 | Exenatide XR | 2 mg | Once weekly | AstraZeneca | 2005 | T2DM |
| Victoza3 | Liraglutide | 1.8 mg | Once daily | Novo Nordisk | 2010 | T2DM |
| Trulicity30 | Dulaglutide | 1.5 mg | Once weekly | Eli Lilly | 2014 | T2DM |
| Adlyxin31 | Lixisenatide | 20 µg | Once daily | Sanofi-Aventis | 2016 | T2DM |
| Ozempic32 | Semaglutide | 1 mg | Once weekly | Novo Nordisk | 2017 | T2DM |
Abbreviations: T2DM, type 2 diabetes mellitus; FDA, Food and Drug Administration; GLP-1, glucagon-like peptide-1; XR, extended release.